Source: Healio News
Subcutaneous elranatamab demonstrated efficacy and a manageable safety profile in patients with relapsed or refractory multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.
Nizar J. Bahlis, MD, from the University of Calgary, reported updates for subcutaneous dosing of elranatamab (PF-0686313, Pfizer), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in relapsed/refractory multiple myeloma from the ongoing phase 1 MagnetisMM-1 study at the virtual ASCO Annual Meeting.
Patients received subcutaneous elranatamab at 80, 130, 215, 360, 600 and 1000 g/kg each